1. THE NEWS: The 2026 PSRM (Reproductive Health and Longevity) Conference in South Korea has unveiled groundbreaking research in reproductive longevity. According to Longevity Korea, the conference featured new genetic interventions to slow ovarian aging and advances in artificial womb technology. Notably, a peptide therapy that increased ovarian reserve by 40% in mice is now ready for human trials.
2. WHY IT MATTERS: These developments could extend women's fertility window globally. While average menopause age is 51, these technologies might preserve fertility into the 60s. In Turkey, where the average age at first birth rose to 28.8 in 2023, millions of women could benefit. The research also offers hope for cancer patients at risk of early menopause due to chemotherapy.
3. CONTEXT & EXAMPLES: Reproductive longevity research isn't new. Japan's mitochondrial replacement therapy in the early 2010s inspired the UK's three-parent IVF in 2020. Today, Korea's work complements ovarian tissue freezing and autotransplantation. WHO data shows over 1 million women enter early menopause yearly; 5% due to genetics, 10% from medical treatments like chemotherapy. The Korean peptide therapy promises a 40% improvement compared to a Swedish study where antioxidants only slowed ovarian aging by 5%. Additionally, a 2024 study in Nature Aging found that rapamycin analogs extended reproductive lifespan in mice by 20%, but the Korean peptide outperforms this.
4. FORWARD LOOK: Within five years, these therapies may enter clinical practice. Ethical debates will arise: Is extending fertility a natural intervention? Will access be equitable? In Turkey, research is nascent, but TÜBİTAK funds a few projects. Korea's progress could reshape reproductive health policies globally. These advances are not just about fertility but also about overall women's health and anti-aging medicine.